Skip to main content

Core value dossiers for medical technologies

Essential tool to support market access and marketing efforts through the lifecycle of the product

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Publication Digest: Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic Areas

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. 

In a recent publication, Heeg et al. proposed a systematic framework to define biologically and clinically plausible survival extrapolations, addressing inconsistencies in current health technology assessments (HTA). Reviewing 29 international HTA guidelines, the authors introduced the DICSA protocol — a five-step process that integrates evidence synthesis with local clinical context to evaluate survival expectations prior to modeling. This framework aims to standardize and enhance the transparency of survival extrapolations, supporting more consistent decision-making in HTA processes.

Access the full-text article here.